12:00 AM
Jul 03, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NeuroCell-PD: Phase III update

In 1999, Genzyme Tissue Repair (GZTR, Cambridge, Mass.) transferred to GENZ its 50 percent interest in a joint venture with Diacrin Inc. Under the agreement, GZTR received $25 million from GENZ, of which $5 million is non-refundable and $20 million is a...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >